Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China

In China, chronic infection with hepatitis B virus (HBV) is estimated to be associated with 60% of cirrhosis and 80% of liver cancer (Wang et al., 2014). Due to the heavy disease burden, the Chinese government recommended HBV vaccination in 1992. In 2002, the vaccine was added to the National Immunization Program schedule for all neonates/infants, with the cost being fully paid for by the government. The latest nationwide study found that the prevalence of hepatitis B surface antigen (HBsAg) had reduced to 0.32% in the age group 1 –4 years and to 0.94% in the age group 5–14 years in 2014, from 9.67% and 10.74%, respectively, in 1992 (Wang et al., 2017a; Xia et al., 1996).

Source: International Journal of Infectious Diseases - November 19, 2018 Category: Infectious Diseases Authors: Yuting Wang, Ju-Fang Shi, Le Wang, Yongfeng Yan, Hongyu Yao, Min Dai, Taoyang Chen, Chunfeng Qu Source Type: research